Belite Bio Inc
Organization details
- Legal name
- Belite Bio Inc
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Cayman Islands
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- BLTE
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001889109
Board of directors
-
Gary Clark Biddle · DirectorSince 2026
-
Hao-Yuan Chuang · Director · Chief Financial OfficerSince 2026
-
Ita Lu · DirectorSince 2026
-
John Michael Longo · DirectorSince 2026
-
Wan-Shan Chen · DirectorSince 2026
-
Xiao-Hui Chen · DirectorSince 2026
-
Yu-Hsin Lin · Director · Chief Executive OfficerSince 2026
Chief executives
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $40,957,466
- 179 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 12, 2026 | Scholl Hendrik Peter Officer (Chief Medical Officer) | Open-market sale | −500 | $162.04 | $81,020 |
| Nov 12, 2026 | Scholl Hendrik Peter Officer (Chief Medical Officer) | Open-market sale | −500 | $164.68 | $82,342 |
| Nov 12, 2026 | Scholl Hendrik Peter Officer (Chief Medical Officer) | Open-market sale | −500 | $166.82 | $83,410 |
| Nov 12, 2026 | Scholl Hendrik Peter Officer (Chief Medical Officer) | Open-market sale | −500 | $170.41 | $85,205 |
| Oct 29, 2026 | Yu-Hsin Lin Director, Officer (Chief Executive Officer) | Other | +5,000 | — | — |
| Oct 29, 2026 | Hao-Yuan Chuang Director, Officer (Chief Financial Officer) | Other | +5,000 | — | — |
| Oct 1, 2026 | Scholl Hendrik Peter Officer (Chief Medical Officer) | Open-market sale | −200 | $163.63 | $32,725 |
| Oct 1, 2026 | Scholl Hendrik Peter Officer (Chief Medical Officer) | Open-market sale | −24 | $164.64 | $3,951 |
| Oct 1, 2026 | Scholl Hendrik Peter Officer (Chief Medical Officer) | Open-market sale | −120 | $165.49 | $19,859 |
| Oct 1, 2026 | Scholl Hendrik Peter Officer (Chief Medical Officer) | Open-market sale | −50 | $166.44 | $8,322 |
| Oct 1, 2026 | Scholl Hendrik Peter Officer (Chief Medical Officer) | Open-market sale | −78 | $167.59 | $13,072 |
| Oct 1, 2026 | Scholl Hendrik Peter Officer (Chief Medical Officer) | Open-market sale | −12 | $168.21 | $2,019 |
| Oct 1, 2026 | Scholl Hendrik Peter Officer (Chief Medical Officer) | Open-market sale | −14 | $169.36 | $2,371 |
| Oct 1, 2026 | Scholl Hendrik Peter Officer (Chief Medical Officer) | Open-market sale | −2 | $170.02 | $340 |
| Sep 24, 2026 | Wan-Shan Chen Director | In-the-money exercise | +13,796 | $0.44 | $6,051 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Belite Bio Inc
Who is the CEO of Belite Bio Inc?
Yu-Hsin Lin has been Belite Bio Inc's Chief Executive Officer since March 2026.
How many directors are on Belite Bio Inc's board?
Belite Bio Inc's board has 7 directors: Gary Clark Biddle, Hao-Yuan Chuang, Ita Lu, John Michael Longo, Wan-Shan Chen, Xiao-Hui Chen and Yu-Hsin Lin.
Are Belite Bio Inc insiders buying or selling shares?
Over the last 12 months, Belite Bio Inc insiders made no open-market purchases and sold $41.0 million of shares in 179 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="belite-bio-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.